Omnicell (OMCL) has been drawing attention after a period of share price weakness, with the stock down about 21% over the past month and 18% over the past 3 months.

At the current share price of $36.03, Omnicell’s momentum has been weak recently, with the share price return down over the past month and year to date, while the 1 year total shareholder return remains positive but longer term total shareholder returns are still deeply negative.

If Omnicell’s recent pullback has you reassessing your watchlist, this can be a good moment to look at other healthcare technology opportunities through our screener for 40 healthcare AI stocks.

Omnicell now trades at a clear discount to both analyst targets and some estimated fair value measures after its slide. Is that a mispricing, or is it a signal that the market’s caution on the stock is warranted?

Most Popular Narrative: 41.2% Undervalued

Omnicell's most followed valuation narrative puts fair value at $61.29, which sits well above the recent $36.03 close and frames the current discount.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Want to see what sits behind that OmniSphere driven shift to recurring revenue? The narrative focuses on revenue mix, margin changes and a potentially richer earnings profile.

Result: Fair Value of $61.29 (UNDERVALUED)

However, Omnicell’s story can change quickly if tariff costs erode margins or if hospital capital budgets tighten and slow large automation projects.

Another View On Omnicell’s Valuation

The earlier narrative leaned on future earnings and fair value estimates around $61.29 to frame Omnicell as undervalued. On current numbers, the picture looks different. Omnicell trades on a P/E of 42.1x, compared with a fair ratio of 27.9x, the US Medical Equipment industry at 26.2x and peer average of 29x. That implies investors today are paying a much richer multiple for each dollar of earnings, which can raise valuation risk if expectations slip. So is this a genuine long term opportunity, or is the market already pricing in a lot of the good news?

Next Steps

Given the mixed tone around Omnicell’s current valuation and rewards, it makes sense to check the underlying numbers yourself and move quickly. To see what investors are optimistic about and why some still see upside potential, review the 4 key rewards

Looking for more investment ideas beyond Omnicell?

If Omnicell is already on your radar, do not stop there. Use the Simply Wall Street screener to uncover fresh ideas that could strengthen your portfolio.

• Target dependable income by scanning companies that qualify as 10 dividend fortresses and see which ones suit your long term cash flow goals.
• Hunt for quality at a marked down price by reviewing our list of 53 high quality undervalued stocks that meet strict fundamental checks.
• Prioritise resilience by focusing on 80 resilient stocks with low risk scores that combine sturdier balance sheets with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.